Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Urogen Pharma Ltd's Business Segments
Urogen Pharma Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Zusduri
Total Revenue
$ 72
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Zusduri0%
- Jelmyto60.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Zusduri | $ 80 | - |
| Jelmyto | $ 44 | 60.4% |
Revenue by Product & Service Category - FY
- Zusduri57.5%
- Jelmyto42.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Zusduri | $ 29 | 57.5% |
| Jelmyto | $ 22 | 42.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Zusduri0%
- Jelmyto60.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Zusduri | $ 80 | - |
| Jelmyto | $ 44 | 60.4% |
Description of Urogen Pharma Ltd
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing innovative therapies for urological and oncological diseases. The company is dedicated to improving the quality of life for patients suffering from these conditions by providing effective and targeted treatment options.
One of the key areas of focus for Urogen Pharma Ltd is in the development of novel therapies for bladder cancer. Bladder cancer is one of the most common types of cancer, and current treatment options often have limited effectiveness and significant side effects. Urogen Pharma Ltd aims to address these limitations by developing therapies that specifically target the tumor cells while minimizing damage to healthy tissues.
The company's flagship product is UGN-101, a non-surgical treatment for low-grade upper tract urothelial cancer (UTUC). UGN-101 is administered locally through the ureter, allowing for targeted therapy that maximizes effectiveness while minimizing systemic side effects. Clinical trials have demonstrated promising results, with high rates of tumor eradication and a favorable safety profile.
In addition to its focus on bladder cancer, Urogen Pharma Ltd is also actively engaged in research and development for other urological and oncological diseases. The company is exploring potential therapies for prostate cancer, kidney cancer, and other urological conditions such as overactive bladder and urinary incontinence.
Urogen Pharma Ltd takes a comprehensive approach to drug development, combining cutting-edge science with rigorous clinical research and regulatory expertise. The company has a team of experienced scientists, clinicians, and industry professionals who work collaboratively to bring therapies from the laboratory to clinical trials and ultimately to market.
Furthermore, Urogen Pharma Ltd is committed to collaboration and partnerships to accelerate the development and commercialization of its therapies. The company has established collaborations with leading academic institutions, research organizations, and pharmaceutical companies to leverage their expertise and resources.
In terms of corporate governance and social responsibility, Urogen Pharma Ltd adheres to the highest ethical and legal standards. The company is committed to conducting its business in a responsible and sustainable manner, promoting patient safety and welfare, and complying with all relevant regulations and guidelines.
Overall, Urogen Pharma Ltd is a dynamic and innovative pharmaceutical company that is at the forefront of developing novel therapies for urological and oncological diseases. With a strong focus on bladder cancer and a commitment to scientific excellence and patient care, the company is poised to make a significant impact in the field of urology and oncology.
One of the key areas of focus for Urogen Pharma Ltd is in the development of novel therapies for bladder cancer. Bladder cancer is one of the most common types of cancer, and current treatment options often have limited effectiveness and significant side effects. Urogen Pharma Ltd aims to address these limitations by developing therapies that specifically target the tumor cells while minimizing damage to healthy tissues.
The company's flagship product is UGN-101, a non-surgical treatment for low-grade upper tract urothelial cancer (UTUC). UGN-101 is administered locally through the ureter, allowing for targeted therapy that maximizes effectiveness while minimizing systemic side effects. Clinical trials have demonstrated promising results, with high rates of tumor eradication and a favorable safety profile.
In addition to its focus on bladder cancer, Urogen Pharma Ltd is also actively engaged in research and development for other urological and oncological diseases. The company is exploring potential therapies for prostate cancer, kidney cancer, and other urological conditions such as overactive bladder and urinary incontinence.
Urogen Pharma Ltd takes a comprehensive approach to drug development, combining cutting-edge science with rigorous clinical research and regulatory expertise. The company has a team of experienced scientists, clinicians, and industry professionals who work collaboratively to bring therapies from the laboratory to clinical trials and ultimately to market.
Furthermore, Urogen Pharma Ltd is committed to collaboration and partnerships to accelerate the development and commercialization of its therapies. The company has established collaborations with leading academic institutions, research organizations, and pharmaceutical companies to leverage their expertise and resources.
In terms of corporate governance and social responsibility, Urogen Pharma Ltd adheres to the highest ethical and legal standards. The company is committed to conducting its business in a responsible and sustainable manner, promoting patient safety and welfare, and complying with all relevant regulations and guidelines.
Overall, Urogen Pharma Ltd is a dynamic and innovative pharmaceutical company that is at the forefront of developing novel therapies for urological and oncological diseases. With a strong focus on bladder cancer and a commitment to scientific excellence and patient care, the company is poised to make a significant impact in the field of urology and oncology.
Urogen Pharma Ltd is a biopharmaceutical company that primarily focuses on developing and commercializing innovative therapies for urological cancers and other urological conditions. The company’s approach involves leveraging its expertise in drug development to address unmet medical needs, particularly in the areas of bladder cancer and other malignancies affecting the urinary system.
Segments
1. Oncology: Urogen Pharma is heavily involved in the oncology segment, specifically targeting urological cancers such as bladder cancer. The company aims to develop therapies that improve patient outcomes and quality of life.
2. Urology: Beyond oncology, Urogen focuses on broader urological disorders, developing products that can enhance treatment options for a range of conditions affecting the urinary system.
Products
Urogen Pharma’s product portfolio includes both marketed products and candidates in various stages of development:
1. Urothelial Carcinoma Treatments:
- Vicinium: This is an investigational therapeutic agent designed specifically for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC). Vicinium is a localized treatment that targets cancer cells expressing a specific protein, reducing systemic exposure and potential side effects.
- UGN-101 (Instiladrin): Approved for the treatment of patients with low-grade NMIBC, Instiladrin consists of a drug-device combination that uses a non-invasive delivery method. It delivers the active agent directly into the bladder, allowing for localized treatment that minimizes systemic toxicity.
2. Clinical Development Programs:
- Urogen is involved in multiple clinical trials that aim to evaluate the efficacy and safety of new treatments in the urological oncology space. These programs often involve combination therapies, advanced delivery systems, and novel therapeutic approaches.
- UGN-102: This product is designed for patients with upper tract urothelial carcinoma. It represents Urogens commitment to extending treatment options beyond just bladder cancer.
Services
In addition to its pharmaceutical products, Urogen Pharma offers a range of services which may include:
1. Clinical Research and Development: Urogen engages in extensive clinical trials to validate the safety and efficacy of its drug candidates. The company partners with various research institutions and clinical centers to facilitate this research.
2. Regulatory Support Services: The company ensures that its products meet the necessary regulatory requirements for approval by health authorities. This includes navigating the complexities of submissions and approvals in various markets.
3. Patient Support Programs: Urogen Pharma is committed to patient care by offering support programs aimed at helping patients understand their treatment options, manage side effects, and access necessary resources.
4. Educational Initiatives: The company often invests in educational efforts aimed at healthcare providers, enhancing their understanding of urological cancers and available treatments. This is crucial for ensuring that patients receive informed and timely care.
Conclusion
Urogen Pharma Ltd is dedicated to improving the lives of patients suffering from urological cancers through its innovative product offerings and commitment to research. With a focus on both current and emerging therapeutic solutions, Urogen continues to expand its influence in the oncology and urology fields, working towards addressing significant unmet medical needs and advancing the standards of care.
Segments
1. Oncology: Urogen Pharma is heavily involved in the oncology segment, specifically targeting urological cancers such as bladder cancer. The company aims to develop therapies that improve patient outcomes and quality of life.
2. Urology: Beyond oncology, Urogen focuses on broader urological disorders, developing products that can enhance treatment options for a range of conditions affecting the urinary system.
Products
Urogen Pharma’s product portfolio includes both marketed products and candidates in various stages of development:
1. Urothelial Carcinoma Treatments:
- Vicinium: This is an investigational therapeutic agent designed specifically for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC). Vicinium is a localized treatment that targets cancer cells expressing a specific protein, reducing systemic exposure and potential side effects.
- UGN-101 (Instiladrin): Approved for the treatment of patients with low-grade NMIBC, Instiladrin consists of a drug-device combination that uses a non-invasive delivery method. It delivers the active agent directly into the bladder, allowing for localized treatment that minimizes systemic toxicity.
2. Clinical Development Programs:
- Urogen is involved in multiple clinical trials that aim to evaluate the efficacy and safety of new treatments in the urological oncology space. These programs often involve combination therapies, advanced delivery systems, and novel therapeutic approaches.
- UGN-102: This product is designed for patients with upper tract urothelial carcinoma. It represents Urogens commitment to extending treatment options beyond just bladder cancer.
Services
In addition to its pharmaceutical products, Urogen Pharma offers a range of services which may include:
1. Clinical Research and Development: Urogen engages in extensive clinical trials to validate the safety and efficacy of its drug candidates. The company partners with various research institutions and clinical centers to facilitate this research.
2. Regulatory Support Services: The company ensures that its products meet the necessary regulatory requirements for approval by health authorities. This includes navigating the complexities of submissions and approvals in various markets.
3. Patient Support Programs: Urogen Pharma is committed to patient care by offering support programs aimed at helping patients understand their treatment options, manage side effects, and access necessary resources.
4. Educational Initiatives: The company often invests in educational efforts aimed at healthcare providers, enhancing their understanding of urological cancers and available treatments. This is crucial for ensuring that patients receive informed and timely care.
Conclusion
Urogen Pharma Ltd is dedicated to improving the lives of patients suffering from urological cancers through its innovative product offerings and commitment to research. With a focus on both current and emerging therapeutic solutions, Urogen continues to expand its influence in the oncology and urology fields, working towards addressing significant unmet medical needs and advancing the standards of care.